A multi-center retrospective observational study to evaluate PD-L1 protein expression, EBV positivity and the frequency of MSI-H in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japa
- Conditions
- advanced gastric and esophagogastric junction adenocarcinoma
- Registration Number
- JPRN-UMIN000034836
- Lead Sponsor
- Profit organization
- Brief Summary
241/389 (62%) were PD-L1 positive, 24/379 (6.3%) had MSI-H tumors, and 13/389 (3.3%) were EBV positive. Among patients with MSI-H tumors and EBV-positive tumors, 19/24 (79.2%) and 9/13 (69.2%), respectively, were PD-L1 positive. A greater proportion of patients with MSI-H tumors (83.3% [20/24]) were PD-L1 positive than those with MSI-low/stable tumors (60.8% [216/355]; p = .0297)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 391
Not provided
1) Patients with other primary tumor types at the time the tissue sample was collected 2) Patients who had underwent radiation therapy before tumor sampling 3) Patients who had received systemic chemotherapy before tumor sampling 4) Patients with tumor samples that were obtained before 2014 5) Patients with tumor tissues that were thinly sliced more than 6 months ago 6) Patients with less than 100 tumor cells available 7) Patients whose samples are considered to be in an extremely poor preservation condition by the investigators 8) Other patients whose enrollment in the study is considered inappropriate by the investigators
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method